Eurofins Scientific Stock Plummets 10.78% After Disappointing Quarterly Revenue
On Wednesday, shares of the bioanalytical services specialist saw their biggest daily drop in months, falling to €61.88 after closing at €69.36 the previous day. The decline follows this morning's release of the company's first-quarter results, which showed revenue dynamics falling short of expectations despite a notable improvement in margins.
A Slowdown in Business Dynamics
Today's release highlighted a slowdown in business dynamics at Eurofins Scientific. In the first three months of the fiscal year, the group reported organic growth of just 2.5%, hampered by unfavorable weather conditions in Northern Europe and North America, as well as the voluntary termination of unprofitable contracts. While the improvement in profitability and margins is a positive point, investors seem to be primarily concerned with the lack of vigor in revenue.
The 10.78% correction recorded during the session exacerbates a decline that had already begun in recent days: over seven sessions, the stock has lost 9.64%, and it is down 11.63% over three months. The CAC 40 is trading around 8,201 points, down moderately by 0.41%, which underscores the specific nature of the punishment inflicted on Eurofins, well beyond the general trend of the Paris market. The general meeting scheduled for tomorrow, April 23, could provide new insights into the group's strategy.
Technical Perspective on the Day's Decline
From a technical standpoint, today's decline brings the share price closer to its support threshold at €60.76, a level that had not been tested recently. The 50-day moving average, which stands at €65.13, has been significantly breached, indicating a break in the bullish trend that had prevailed in recent weeks. The price is now positioned in the lower part of the Bollinger Bands, at only 23% of the amplitude between the lower bound (€58.97) and the upper bound (€71.50), which indicates significant selling pressure.
This sharp movement contrasts with the update published by Alphavalue, which raised its price target from €73.40 to €77.80 with a recommendation to 'accumulate'. At €61.88, the stock is therefore about 25% below this new target, a significant gap that reflects the current divergence between the fundamental view of the analyst and the market's reaction to the quarterly figures.
